Epstein-barr virus nuclear antigen 1 replication and segregation functions in nasopharyngeal carcinoma cell lines

Journal of Virology

Volumn 85, Issue 19, 2011, Pages 10425-10430

  Sivachandran, Nirojini ^a   Thawe, Natalia N ^a   Frappier, Lori ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; PROTEIN ORIP; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; CANCER CELL CULTURE; CELL STRAIN; CELL STRAIN C666 1; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE FUNCTION; HUMAN; HUMAN CELL; MITOSIS; NASOPHARYNX CARCINOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRUS GENOME;

CELL LINE, TUMOR; CHROMOSOME SEGREGATION; DNA REPLICATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; PLASMIDS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EID: 80053995345     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05293-11     Document Type: Note

References (18)

1. Ceccarelli, D. F. J., and L. Frappier. 2000. Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus. J. Virol. 74:4939-4948.
2. Cheung, S. T., et al. 1999. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83:121-126.
3. de Jesus, O., et al. 2003. Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J. Gen. Virol. 84:1443-1450.
4. Dittmer, D. P., et al. 2008. Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma. Int. J. Cancer 123:2105-2112.
5. Frappier, L. 2010. EBNA1 in viral DNA replication and persistence, p. 37-59. In E. S. Robertson (ed.), Epstein-Barr virus: latency and transformation. Caister Academic Press, Norwich, United Kingdom.
6. Hirai, K., and M. Shirakata. 2001. Replication licensing of the EBV oriP minichromosome. Curr. Top. Microbiol. Immunol. 258:13-33.
7. Holowaty, M. N., et al. 2003. Protein profiling with Epstein-Barr nuclear antigen 1 reveals an interaction with the herpesvirus-associated ubiquitinspecific protease HAUSP/USP7. J. Biol. Chem. 278:29987-29994.
8. Hu, M., et al. 2005. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24:3747-3756.
9. Kapoor, P., B. D. Lavoie, and L. Frappier. 2005. EBP2 plays a key role in Epstein-Barr virus mitotic segregation and is regulated by aurora family kinases. Mol. Cell. Biol. 25:4934-4945.
10. Lindner, S. E., and B. Sugden. 2007. The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 58:1-12.
11. Raab-Traub, N. 2002. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:431-441.
12. Sample, J., E. B. D. Henson, and C. Sample. 1992. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66:4654-4661.
13. Shannon-Lowe, C., et al. 2009. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83:7749-7760.
14. Shire, K., D. F. J. Ceccarelli, T. M. Avolio-Hunter, and L. Frappier. 1999. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance. J. Virol. 73: 2587-2595.
15. Sivachandran, N., F. Sarkari, and L. Frappier. 2008. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog. 4:e1000170.
16. Sun, Y., et al. 1992. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 89:6516-6520.
17. Tao, Q., and A. T. Chan. 2007. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 9:1-24.
18. Yoshioka, M., M. M. Crum, and J. T. Sample. 2008. Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J. Virol. 82:1679-1687.